Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Short Communication
27 January 2021

Real-world healthcare resource utilization and costs of weekly versus every-2-week cetuximab in metastatic colorectal cancer

Authors: Chris P Pescott https://orcid.org/0000-0002-7763-9326 [email protected], Emmanuelle Boutmy https://orcid.org/0000-0001-9657-9376, Michael Batech https://orcid.org/0000-0001-9570-8180, Philippe Ronga, and Francois-Xavier Lamy https://orcid.org/0000-0001-7759-6285Author Info & Affiliations
Volume 10, Number 5
https://doi.org/10.2217/cer-2020-0232
PDFFormats

Abstract

Aim: To compare healthcare resource utilization (HRU) and healthcare costs (HC) for every-2-week (Q2W) versus weekly (Q1W) cetuximab in metastatic colorectal cancer (mCRC). Patients & methods: Patients with mCRC receiving cetuximab plus chemotherapy in a line-agnostic setting. Cohort study of patients with mCRC treated with cetuximab and chemotherapy in IBM MarketScan. Analyses were weighted by inverse probability of treatment based on propensity score. Results: HRU was numerically lower with the Q2W versus Q1W regimen (weighted mean, 8.1 vs 9.5 encounters per-patient-per-month). The weighted average of HC was $17,653 and $16,469 per-patient-per-month for the Q2W and Q1W regimens, respectively; the difference between regimens decreased when restricting to CRC-related claims. Conclusion: HRU was lower and HC were similar between the Q2W and Q1W regimens.

Supplementary Material

File (suppl_file.docx)

References

Papers of special note have been highlighted as: • of interest
1.
American Cancer Society. Key statistics for colorectal cancer (2020). www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html
Google Scholar
2.
Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat. Rev. Gastroenterol. Hepatol. 16(12), 713–732 (2019).
PubMed
Google Scholar
3.
Siegel RL, Miller KD, Goding Sauer A et al. Colorectal cancer statistics, 2020. CA Cancer J. Clin. 70(3), 145–164 (2020).
PubMed
Google Scholar
4.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 4. 2020. www.nccn.org/professionals/physician_gls/pdf/colon.pdf
Google Scholar
5.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. Version 6. 2020. www.nccn.org/professionals/physician_gls/pdf/rectal.pdf
Google Scholar
6.
García-Foncillas J, Sunakawa Y, Aderka D et al. Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors. Front. Oncol. 9, 849 (2019).
PubMed
Google Scholar
7.
Dekker E, Tanis PJ, Vleugels JLA et al. Colorectal cancer. Lancet 394(10207), 1467–1480 (2019).
PubMed
Google Scholar
8.
FDA. Erbitux (cetuximab). Prescribing information (2019). www.accessdata.fda.gov/drugsatfda_docs/label/2019/125084s273lbl.pdf
Google Scholar
9.
Mrabti H, De la Fouchardiere C, Desseigne F et al. Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer. J. Cancer Res. Ther. 5(4), 272–276 (2009).
PubMed
Google Scholar
10.
Yeh Y-S, Chiang C-Y, Chen C-J et al. Efficacy and safety of weekly and biweekly cetuximab-combined FOLFIRI regimen as first-line setting in patients with metastatic colorectal cancer: experience in a southern Taiwan medical center. J. Soc. Colon Rectal Surgeon (Taiwan). 21, 59–68 (2010).
Google Scholar
11.
Brodowicz T, Ciuleanu TE, Radosavljevic D et al. FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study. Ann. Oncol. 24(7), 1769–1777 (2013).
PubMed
Google Scholar
12.
Li J, Li J. Therapeutic effect of biweekly cetuximab combined with first-line chemotherapy on KRAS/RAS wild-type advanced colorectal cancer. Int. J. Clin. Exp. Med. 12(10), 12348–12355 (2019).
Google Scholar
13.
Tabernero J, Pfeiffer P, Cervantes A. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? Oncologist 13(2), 113–119 (2008).
PubMed
Google Scholar
14.
NICE. NICE Guidance: cetuximab and panitumumab for previously untreated metastatic colorectal cancer (2017). www.nice.org.uk/Guidance/ta439
Google Scholar
15.
Phelip JM, Tougeron D, Leonard D et al. Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig. Liver Dis. 51(10), 1357–1363 (2019).
PubMed
Google Scholar
16.
Lamy F-X, Batech M, Boutmy E et al. Comparative effectiveness of weekly versus every-2-weeks cetuximab in metastatic colorectal cancer in a US insured population. J. Comp. Eff. Res. 9(16), 1117–1129 (2020).
PubMed
Google Scholar
17.
Song X, Zhao Z, Barber B et al. Characterizing medical care by disease phase in metastatic colorectal cancer. Am. J. Manag. Care. 17(Suppl. 5), SP20–SP25 (2011).
PubMed
Google Scholar
• Describes an algorithm that can be used to empirically identify and prioritize candidate covariates in order to integrate them into a propensity score-based confounder adjustment model.
18.
Paramore LC, Thomas SK, Knopf KB et al. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin. Colorectal Cancer. 6(1), 52–58 (2006).
PubMed
Google Scholar
• Describes the resource use patterns and costs of care for patients with metastatic colorectal cancer using retrospective claims data from selected US health plans.
19.
Schneeweiss S, Rassen JA, Glynn RJ et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20(4), 512–522 (2009).
PubMed
Google Scholar
• Describes a statistical approach that can be used to obtain appropriate estimates of variance of the main effects in regression models for the purpose of performing inverse probability of treatment weighting to reduce selection bias.
20.
Xu S, Ross C, Raebel MA et al. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health 13(2), 273–277 (2010).
PubMed
Google Scholar
21.
Kasper S, Cheng A, Overkamp F et al. Noninferiority on overall survival of every-2-weeks vs weekly schedule of cetuximab for first-line treatment of RAS wild-type metastatic colorectal cancer. Ann. Oncol. 30(Suppl. 5), v198–v252 (2019).
Google Scholar
22.
Brodowicz T, Vrbanec D, Kaczirek K et al. FOLFOX4 plus cetuximab administered weekly or every two weeks in first-line treatment of patients with KRAS and NRAS wild-type (wt) metastatic colorectal cancer (mCRC). J. Clin. Oncol. 32(Suppl. 3), LBA391 (2017).
Google Scholar
23.
Lamy FL, Batech M, Salim S et al. Real-world study of cetuximab used every other week versus weekly in US patients with metastatic colorectal cancer (mCRC). J. Clin. Oncol. 37(Suppl. 15), e15087 (2019).
Google Scholar
|